Scientists have hailed the drug, called lorlatinib, for its “off the charts” results after a trial found it improved survival rates by the longest period ever recorded. In the trial ...

Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of breast cancer-specific survival. ...HER3 expression was... significantly associated with ...